Separately, Piper Sandler raised their price objective on Supernus Pharmaceuticals from $42.00 to $43.00 and gave the stock an overweight rating in a research note on Thursday, November 9th.
Supernus Pharmaceuticals Stock Down 0.4 %
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last released its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.42). The company had revenue of $153.88 million for the quarter, compared to the consensus estimate of $143.39 million. Supernus Pharmaceuticals had a return on equity of 2.82% and a net margin of 4.20%. The business’s revenue was down 13.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.03 earnings per share. On average, equities research analysts anticipate that Supernus Pharmaceuticals will post 1.59 EPS for the current fiscal year.
Insider Transactions at Supernus Pharmaceuticals
In other news, VP Tami Tillotson Martin sold 5,135 shares of the firm’s stock in a transaction on Friday, August 25th. The stock was sold at an average price of $31.59, for a total value of $162,214.65. Following the completion of the sale, the vice president now owns 85,249 shares of the company’s stock, valued at $2,693,015.91. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, SVP Frank Mottola sold 1,110 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $28.13, for a total transaction of $31,224.30. Following the completion of the sale, the senior vice president now owns 5,681 shares of the company’s stock, valued at $159,806.53. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Tami Tillotson Martin sold 5,135 shares of Supernus Pharmaceuticals stock in a transaction on Friday, August 25th. The shares were sold at an average price of $31.59, for a total value of $162,214.65. Following the sale, the vice president now directly owns 85,249 shares of the company’s stock, valued at approximately $2,693,015.91. The disclosure for this sale can be found here. Insiders sold a total of 23,438 shares of company stock valued at $711,789 over the last quarter. Company insiders own 8.76% of the company’s stock.
Institutional Trading of Supernus Pharmaceuticals
A number of institutional investors have recently bought and sold shares of SUPN. Glass Jacobson Investment Advisors llc acquired a new stake in Supernus Pharmaceuticals during the second quarter valued at $30,000. China Universal Asset Management Co. Ltd. raised its holdings in Supernus Pharmaceuticals by 96.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,401 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 687 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in Supernus Pharmaceuticals by 41.6% during the third quarter. Public Employees Retirement System of Ohio now owns 1,253 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 368 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Supernus Pharmaceuticals by 389.7% during the first quarter. Tower Research Capital LLC TRC now owns 1,327 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 1,056 shares in the last quarter. Finally, Point72 Middle East FZE bought a new position in Supernus Pharmaceuticals during the fourth quarter valued at about $57,000.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
- Five stocks we like better than Supernus Pharmaceuticals
- What Are Dividend Challengers?
- The most upgraded stocks in November have two things in common
- How to Buy Gold Stock and Invest in Gold
- Monday.com rocked earnings like it’s the weekend
- What Are the FAANG Stocks and Are They Good Investments?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.